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ABSTRACT
This study evaluated the application of the French
guidelines for prevention of neonatal group B
streptococcus (GBS) infections. The prevalence of
GBS vaginal carriage by pregnant women during
the study period was 6%. Less than 50% of
pregnant women testing positive for GBS were
treated with at least two doses of antibiotics
during labour, and most received only one dose
or no antibiotics. In addition, several neonates
were colonised or infected by GBS although their
mothers were GBS-negative. These results are
consistent with vaginal screening having a poor
sensitivity, as suggested by the low prevalence of
GBS carriage.
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Various guidelines have been published in
developed countries for reducing group B strep-
tococcus (GBS) neonatal infections, especially
early-onset disease [1–5]. In France, guidelines
for reducing the neonatal risk of early bacterial
infections were published in September 2001 [6],
and these recommend vaginal screening between
weeks 34 and 38 of pregnancy to allow intra-
partum antibiotic prophylaxis to be given, if
needed, to GBS carriers during labour [6]. Rectal
screening is not recommended; neither is selective
enrichment in liquid medium or on a speciﬁc agar
medium. Systemic antibiotic prophylaxis is ap-
propriate if neonatal GBS infection had occurred
during a previous pregnancy, if GBS bacteriuria
occurred during the current pregnancy, or if GBS
carriage was detected at any time during the
current pregnancy. Antibiotic prophylaxis is also
recommended if no vaginal sample is available
for GBS screening and one of the following risk-
factors is present: labour before 37 weeks of
pregnancy; membranes ruptured for >12 h; or
maternal temperature >38C during labour [6].
The present prospective study evaluated the
application of GBS screening in the maternity unit
of the Tours University Hospital, France, which
delivers 3800 babies annually. The results of all
vaginal GBS screens of pregnant women were
collected between March 2004 and September
2004, together with the results of gastric ﬂuid and
placental cultures for the corresponding neonates.
When positive results for GBS were obtained,
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data concerning the pregnancy, delivery and
post-partum period were collected. In addition,
the midwives and obstetricians caring for the
pregnant women were asked to complete a short
anonymous questionnaire concerning their prac-
tices for systematic GBS screening; this ques-
tioned their knowledge of the indications for
screening and its exceptions, the precise time
recommended for vaginal screening, the precise
anatomical site for swabbing, etc.
During the study period, 1460 vaginal screens
were performed, of which 87 (6%) were positive.
Of the 87 GBS-positive pregnant women, eight
subsequently underwent elective Caesarian deliv-
eries, 38 were treated with at least two doses of
antibiotics during labour (36 were treated initially
with 5 MU and then with 2.5 MU of intravenous
penicillin G every 4 h until delivery, and two
were treated with rovamycin because of b-lactam
allergy), 33 received only one dose of antibiotic
(usually because of a lengthy delay between
arrival at the maternity unit and the start of
intra-partum antibiotic prophylaxis) and eight
received no antibiotics (ﬁve because of the short
period between arrival at the hospital and deliv-
ery, and three because the screening result was not
available during labour). Only two neonates were
found to be colonised or infected by GBS when
their mothers were treated correctly with at least
two doses of antibiotics (5.2% transmission from
mothers to newborns), whereas eight neonates
were colonised or infected when their mothers
had received either one dose of antibiotics or no
antibiotics (19.5% transmission from mothers to
newborns). Of the babies born to the 1373 women
with negative GBS screening results, 25 (1.8%)
were colonised or infected by GBS. Although the
transmission rate in negative cases was low, if the
range of GBS transmission from colonised moth-
ers to newborns is 40–70% [7], this corresponds to
35–60 women being colonised by GBS.
Of the 15 midwives and obstetricians who
received the questionnaire, 13 replied anony-
mously within 10 days. Only eight of the prac-
titioners knew the precise time recommended
for vaginal screening, whereas the other ﬁve
thought that the screening period either began
after 35 weeks or ﬁnished before 38 weeks. Only
one practitioner was aware of the exceptions to
the policy, whereas the other 12 were mistaken
for at least one indication. None of the respond-
ents carried out screening exactly as speciﬁed in
the guidelines; either the vaginal swab included
the whole of the vaginal cavity but focused
on the top half of the vagina, or the vaginal
swab was limited to the top half of the vagina.
The prevalence of vaginal GBS carriage in the
study was consistent with the ﬁndings of a
recent multicentre French study involving 23
laboratories, in which the prevalence was 5.1–
22.5%, with half of the laboratories showing a
prevalence of <10% [8]. Variations in GBS
carriage may be caused by different sampling
procedures for the vaginal swabs (see below),
and may also be explained by different labor-
atory procedures. For example, the prevalence
was 6.9% when using a transport medium but
no enrichment medium [9], compared with
11.1% without transport medium but with
enrichment medium [10]. This is important
because the French guidelines do not recom-
mend rectal screening in combination with
vaginal screening, and do not recommend using
selective enrichment in liquid medium or on a
speciﬁc agar medium so that the guidelines can
be applied by all French laboratories. However,
as the guidelines consider prevention strategies
based on models in which vaginal and recto-
vaginal colonisation rates were 14.7% and
22.8%, respectively [11], sampling and labora-
tory procedures should be able to detect GBS
prevalence within this range. A lack of sensi-
tivity will result in unsuspecting women carriers
transmitting GBS, as shown by the colonisation
(or infection) of 25 neonates born to GBS-
negative mothers; however, this may be linked,
in part, to the variability in GBS carriage during
pregnancy [12].
A difference was observed between mother-to-
neonate GBS transmission in women receiving at
least two doses of antibiotics and women receiv-
ing none or only one dose. This suggests that
antibiotic treatment should commence as early as
possible at the start of labour, and as early as
possible after admission to the maternity unit,
as vertical transmission of GBS is greatly
reduced 2 h after beginning antibiotic prophy-
laxis [13].
Although the guidelines were generally well-
known to the practitioners, the behaviour of the
midwives could be improved in two ways. First,
there should be better knowledge of the excep-
tions to the vaginal screening policy that leads
to systemic antibiotic prophylaxis [6]. If these
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exceptions are not known, and if an incorrectly
performed vaginal GBS screen at the end of the
pregnancy is negative, these women will not
receive antibiotics during labour. Second, there
should be better knowledge of the exact anatom-
ical area for sampling (i.e., from the whole of the
vaginal cavity, including the walls of the lower
half of the vagina as far as the vestibule of the
vagina and vulva [6]). This misunderstanding
probably explains, in part, the apparent low
prevalence of vaginal GBS.
In conclusion, this study emphasised the need
to evaluate the methods used for antenatal
screening, and to provide midwives and obstetri-
cians with appropriate education before investi-
gating the effectiveness of the guidelines for
preventing GBS disease.
ACKNOWLEDGEMENTS
We would like to thank all midwives and obstetricians of the
maternity unit (Department of Gynaecology and Obstetrics,
Tours University Hospital, France) for their help in this study
and for answering the questionnaire.
REFERENCES
1. Dutch Organisation of Obstetrics and Gynaecology. Pre-
vention of perinatal group B streptococcal disease. Gynaecol-
ogy guideline 12. Utrecht: NVOG, 1998.
2. Schrag SJ, Gorwitz R, Fultz-Butts K, Schuchat A. Preven-
tion of perinatal group B streptococcal disease: revised
guidelines from CDC. MMWR Recomm Rep 2002; 51: 1–22.
3. Anonymous. Pre´vention des infections pe´rinatales a` strep-
tocoques du groupe B. Recommandations Du Conseil Supe´rieur
d’Hygie`ne de Belgique. Brussels: Conseil Supeﬁeur d’Hygi-
e`ne de Belgique, 2003.
4. Health Protection Agency GBS Working Group. Interim
‘good practice’ recommendations for the prevention of early
onset neonatal group B streptococcal infection in the United
Kingdom. London: Health Protection Agency, 2004.
5. Campbell N, Eddy A, Darlow B, Stone P, Grimwood K.
The prevention of early-onset neonatal group B strepto-
coccus infection: technical report from the New Zealand
GBS Consensus Working Group Party. NZMed J 2004; 117:
1–19.
6. Anonymous. Pre´vention ante´natale du risque infectieux
bacte´rien ne´onatal pre´coce. Recommendations pour la pra-
tique clinique. Paris: Agence Nationale d’Accre´ditation
et d’Evaluation en Sante´, 2001.
7. Gotoff SP. Group B streptococcal infections. Pediatr Res
2002; 23: 381–386.
8. Loulergue J, Couhe´ C, Grasmick C, Laudat P, Quentin R.
Sensibilite´ aux antibiotiques des souches de streptocoque
du groupe B de portage vaginal isole´es en France, 2003.
Bull Epidemiol Hebdom 2004; 18: 69–70.
9. Chhhuy T, Mansour G, Zejli A, Bouquigny C, Bock S,
Abboud P. Group B streptococcus screening: a retrospec-
tive study in 1,674 pregnancies. J Gynecol Obstet Biol Reprod
2005; 34: 328–333.
10. Jaure´guy F, Carton M, Teboul J et al. Risk factors and
screening strategy for group B streptococcal colonization
in pregnant women: results of a prospective study.
J Gynecol Obstet Biol Reprod 2003; 32: 132–138.
11. Benitz WE, Gould JB, Druzin ML. Preventing early-onset
group B streptococcal sepsis: strategy development using
decision analysis. Pediatrics 1999; 103: e76.
12. Hansen SM, Uldbjerg N, Kilian M, Sorensen UB. Dynam-
ics of Streptococcus agalactiae colonization in women during
and after pregnancy and in their infants. J Clin Microbiol
2004; 42: 83–89.
13. de Cueto M, Sanchez MJ, Sampedro A, Miranda JA, Her-
ruzo AJ, Rosa-Fraile M. Timing of intrapartum ampicillin
and prevention of vertical transmission of group B strep-
tococcus. Obstet Gynecol 1998; 91: 112–114.
324 Clinical Microbiology and Infection, Volume 13 Number 3, March 2007
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 316–346
